[Therapeutic use of intravenous immunoglobulins in the antiphospholipid syndrome].
Although experience remains limited and uncontrolled, intravenous immunoglobulin (IVIg) therapy probably has a place in the management of selected patients with the antiphospholipid syndrome. It seems effective for the prevention of recurrent pregnancy losses when conventional strategies using subcutaneous heparin and low-dose aspirin have failed. IVIg are currently investigated in the treatment of recurrent in vitro fertilization failure associated with antiphospholipid antibodies. In patients with severe thrombocytopenia, IVIg usually induce a prompt but transient remission. Finally, IVIg associated with steroids and heparin might improve survival in the rare but life-threatening catastrophic antiphospholipid syndrome.
Piette
J C
JC
Service de Médecine Interne, Groupe Hospitalier Pitié-Salpêtrière, Paris. jean-charles.piette@psl.ap-hop-paris.fr
Lê Thi Huong
D
D
Wechsler
B
B
D000026:Abortion, Habitual / Q000209:etiology / Q000517:prevention & control; D000022:Abortion, Spontaneous / Q000209:etiology / Q000517:prevention & control; D000925:Anticoagulants / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000628:therapy*; D001241:Aspirin / Q000627:therapeutic use; D005260:Female; D005307:Fertilization in Vitro; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011247:Pregnancy; D013921:Thrombocytopenia / Q000628:therapy
D000925:Anticoagulants; D016756:Immunoglobulins, Intravenous; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D001241:Aspirin